Sanofi Aktie
| 103,28EUR | 0,84EUR | 0,82% |
WKN: 920657 / ISIN: FR0000120578
Aktionärsstruktur
| Inhaber | in % |
|---|---|
| Freefloat | 90,65 |
| Plan d'Epargne Entreprise Sanofi Synthelabo | 1,80 |
| Sanofi | 0,79 |
| Caisse de Dépôt & Placement du Québec | 0,59 |
*Die Summe der Anteile kann 100% überschreiten, da bestimmte Anteilseigner zum Freefloat dazu gerechnet wurden.
Personal
| 2017 | 2018 | 2019 | 2020 | 2021 | |
|---|---|---|---|---|---|
| Personal am Ende des Jahres | 106 566 | 104 226 | 100 409 | 99 412 | 95 442 |
| Umsatz pro Mitarbeiter in Mio. EUR | 0,33 | 0,33 | 0,36 | 0,36 | 0,40 |
Bilanz (in Mio. EUR) - Aktiva
| 2017 | 2018 | 2019 | 2020 | 2021 | |
|---|---|---|---|---|---|
| Summe Umlaufvermögen | 26 352 | 24 579 | 28 611 | 33 703 | 30 564 |
| Summe Anlagevermögen | 73 690 | 83 516 | 84 867 | 86 676 | 91 095 |
| Summe Aktiva | 99 826 | 111 408 | 112 736 | 114 529 | 120 242 |
Bilanz (in Mio. EUR) - Passiva
| 2017 | 2018 | 2019 | 2020 | 2021 | |
|---|---|---|---|---|---|
| Gesamtverschuldung/ -verbindlichkeiten | 15 601 | 24 640 | 25 933 | 23 675 | 22 414 |
| Summe Fremdkapital | 41 568 | 52 373 | 53 628 | 51 382 | 51 211 |
| Summe Eigenkapital | 58 258 | 59 035 | 59 108 | 63 147 | 69 031 |
| Summe Passiva | 99 826 | 111 408 | 112 736 | 114 529 | 120 242 |
Adresse
| 54, rue La Boétie, 75008 Paris | |
| Telefon | +33 (1) 53-77-40-00 |
| Fax | +33 (1) 53-77-44-03 |
| Internet | http://www.sanofi.com |
Management
|
Alexandra Roger
Head-Securities Law & Capital Markets |
|
Arnaud Delépine
Investor Relations Officer |
|
Arnaud Robert
Chief Digital Officer & Executive Vice President |
|
Barbara Lavernos
Independent Director |
|
Brendan OCallaghan
Executive Vice President & Head-Industrial Affairs |
|
Christophe Babule
Director |
|
Claire Terrazas
Vice President-Corporate Legal Affairs |
|
Diane D. Souza
Independent Director |
|
Dietmar P. Berger
Chief Medical Officer & Global Head-Development |
|
Eva Schäfer-Jansen
Investor Relations Contact |
|
Fabienne Lecorvaisier
Independent Director |
|
Gilles Schnepp
Independent Director |
|
Jean-Baptiste Chasseloup de Chatillon
Chief Financial Officer & Executive Vice President |
|
John C. Reed
EVP & Global Head-Research & Development |
|
Josep Catlla
Head-Communication |
|
Julie van Ongevalle
Executive VP & Head-Consumer Healthcare |
|
Lise Kingo
Independent Director |
|
Natalie Bickford
Chief People Officer & Executive Vice President |
|
Nestle Frank
Global Head-Immunology Therapeutic Research Area |
|
Noel Geoffroy
Head-North America Consumer Healthcare |
|
Olivier Antoine M. Charmeil
Executive Vice President-General Medicines |
|
Patrick Kron
Independent Director |
|
Paul Hudson
Chief Executive Officer & Director |
|
Rachel Duan
Independent Non-Executive Director |
|
Raj Verma
Chief Diversity, Culture & Experience Officer |
|
Roy Papatheodorou
General Counsel |
|
Serge Weinberg
Chairman |
|
Thomas C. Südhof
Independent Director |
|
William J. Sibold
Executive Vice President-Sanofi Genzyme |
|
Wolfgang Laux
Director |
|
Yann Tran
Director |
ETF-Sparplan
Oskar ist der einfache und intelligente ETF-Sparplan. Er übernimmt die ETF-Auswahl, ist steuersmart, transparent und kostengünstig.
